Answers are grounded in this paper and cite their sources.
Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.
No takes yet. Share an insight, caveat, or question.
Goldney et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: